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Background/aim: We aimed to evaluate the importance of maspin expression in testicular tumors with germ cells, its effect on prognosis,
and the relation with angiogenesis factors.
Materials and methods: The paraffin blocks of the orchiectomy materials of 32 patients who had undergone orchiectomy due to
testicular tumors were taken within the scope of the study. The specimens of the cases included in the study group were reexamined
under light microscope.
Results: While just one maspin-positive sample was found in the seminoma cases, maspin stained positively in 6 of the nonseminoma
germ cell tumors (NSGCTs). No statistical difference was found between maspin and tumor stage, size, alpha fetoprotein values,
vascular endothelial growth factor, Ki-67, and CD31. A statistically positive correlation was only determined between maspin and p53
(P < 0.001).
Conclusion: Maspin protein, whose expression in some tumors is accepted as a poor prognostic factor, is also expressed in testicular
tumors with germ cells. However, according to our study, it is difficult to say whether this protein is a favorable or poor prognostic
factor in testicular tumors and to understand how the effect mechanism works. The positive correlation between maspin and p53 in the
NSGCTs makes us think that maspin might have displayed an effect on the p53 pathway.
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1. Introduction
Maspin (mammary serine protease inhibitor, serpin B5)
is a serine protease inhibitor in the serine superfamily
(1). Serine protease inhibitors are a large protein family
related to inflammation, apoptosis, angiogenesis, and
embryogenesis (2). Maspin is an intracellular protein that
can dissolve in cytoplasm and can be found in different
locations in the cell (3). The varied locations are important
because abnormal localization in some tissues indicates
neoplasia. For instance, whereas maspin in cytoplasm is
associated with a poor prognosis, maspin in the nucleus is
associated with benign lesions (2,3).
Maspin has been studied in many organs in the body (1–
4). Most studies are related to prostate cancer in urology. A
high rate of maspin release was shown in normal prostate
epithelium cells. However, maspin release decreased in
cells with prostate cancer and disappeared in metastases
(4,5). Researchers have suggested that maspin positivity in
* Correspondence: drhuseyin@hotmail.com

prostate and lung cancer had an apoptosis-like effect (6). In
a study carried out on renal tumors, cytoplasmic staining
of maspin in kidney tumors was shown, and in renal
cell carcinomas, the decrease in maspin expression was
correlated with tumor growth and advanced pathologic
stage. Therefore, the decrease in maspin expression was
thought to be associated with a poor prognosis (7).
No detailed study related to maspin and the testes
(normal testis tissue or tumors) has been published in the
literature. Only two studies gave brief information about
the fact that there is maspin expression in testis tissue
(8,9). No studies have shown a relation between maspin
and testicular tumors. In this study, the presence of maspin
expression in the testis and the effects of maspin protein
on tumor progression were evaluated, and its relation with
angiogenesis factors such as vascular endothelial growth
factor (VEGF), p53, Ki-67, and thrombocyte endothelium
adhesion molecule-1 (PCAM-1 or CD31) was examined.
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2. Materials and methods
Paraffin blocks in the archives of the Başkent University
Faculty of Medicine’s Department of Pathology, comprising
orchiectomy material from 32 patients diagnosed with a
germ cell tumor (GCT) after they had undergone radical
(inguinal) orchiectomy due to testis tumors, were used in
this study. The study was approved by the Başkent University
ethics committee. Sections from the paraffin blocks of 5
µm that included the entire tumor (seminomatous and
nonseminomatous tumor areas were separated in mixed
germ cell tumors) were prepared, and the sections were
put on polylysine slides. CD-31 (Biocare, REF-CM347A,
LOT101209-R1, 1/300 dilution), Ki-67 (Spring, Clone
D0-7, RTU), and maspin (Lifespan, LOT# 18780, 1/50
dilution) primary antibodies were applied with a standard
immunohistochemical staining procedure. The specimens
were then screened under a light microscope. Brown-orange
staining was accepted as positive owing to the chromogen
used.
The mean age of the 32 GCT patients was 30.3 years
(between 19 and 63). After the patient files were reexamined
and the age and preoperative human chorionic gonadotropin
(hCG) and alpha fetoprotein (AFP) values were obtained
from the pathology reports and samples stained with
hematoxylin and eosin, data on the histological type,
tumoral mass size, tumor stage, lymphovascular invasion,
rete testis stiffness, and lymph node stiffness were collected.
The comparisons and statistical analyses were performed
using the prognostic factors in the European Association of
Urology’s (EAU) testicular tumor guidelines (10).
2.1. Histopathologic evaluation
The positive staining pattern of the maspin protein was
examined in the nucleus and cytoplasm of the tumor
cells: cytoplasmic staining for VEGF and nuclear staining
for p53. No nuclear staining was detected with maspin
in any material. Positivity was assessed as 0 (1%–5% cells
positive), + (6%–50% cells positive), and ++ (51%–100%
cells positive). The positively stained cell count rate was
calculated in approximately 1000 tumor cells in five large
magnification areas for Ki-67 (5-HPF, 400× magnification).
CD-31 was calculated by eliciting the average number of
veins in five large magnification areas.
2.2. Statistical analyses
In the statistical assessment of the results, SPSS 14.0 was
used. To examine correlations, Pearson correlation analysis
was used; to test the significance of different series, Fisher’s
exact test (with two methods) was used; and to compare
the groups, one-way ANOVA was applied. The results were
accepted as statistically significant at P < 0.05.
3. Results
The distribution of the cases according to tumor stages
was T1: 15, T2: 12, T3: 1, and T4: 4. Fourteen patients had
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pure seminomas, 18 patients had nonseminoma germ cell
tumors (NSGCTs), only one had embryonal carcinoma,
and the rest had mixed components. The maspinpositive staining pattern was examined in tumor cells in
the cytoplasm and the nucleus. No nuclear staining was
detected. Although only 1 out of 14 seminoma cases was
positive for maspin, 6 out of 18 NSGCTs were positive for
maspin (Figures 1A and 1B). The stages were evaluated
in terms of maspin positivity by setting up binary groups
among them, and no difference was detected statistically
between the stages. The P-values were T1–T2, P = 0.05;
T1–T4, P = 0.39; and T2–T4, P = 0.18. No further statistics
were produced since there was only 1 patient with aT3
stage tumor. The patients’ tumor sizes were separated
into two groups: ≤4 cm and ≥4 cm. The relation between
maspin and tumor size was assessed for the two groups. No
statistical correlation was detected (P > 0.05). Serum AFP
and HCG values of the mixed GCT cases were studied.
All patients’ HCG values were below 5000 mIU/mL when
classified in accordance with the EAU guidelines. Although
the AFP values for 14 AFP-positive patients were below
1000, in two patients, the values were between 1000 and
10,000, and in one patient, the value was above 10,000. The
statistical analysis showed no correlation between maspin
positivity and AFP (P > 0.05).The patients’ HCG values
were below 5000 mIU/mL, and no statistically significant
relation was determined between maspin positivity and
HCG.
The positive staining pattern for VEGF was accepted as
cytoplasmic positive staining in tumor cells. In 8 cases of
seminomas, less than 5% staining occurred or no staining
took place at all. In the cases of NSGCTs, in 11 patients,
there was more than 50% (2+) staining. No significant
relation was detected between maspin and VEGF in
patients with seminomas (P > 0.05). Similarly, no relation
was determined between maspin and VEGF in NSGCTs
(P > 0.05).
In p53 evaluation, the positive staining pattern was
nuclear (Figures 1C and 1D). In 3 seminoma cases, p53
stained positively in more than 50% of the cells; however,
more than 50% staining occurred in 10 of the NSGCT
cases. No staining occurred in one seminoma case. This
was the only maspin-positive case among the seminomas.
No statistically significant difference was detected between
maspin and p53 in cases of seminoma (P > 0.05). In the
statistical analysis conducted on NSGCTs, there was a
positive correlation between maspin and p53 (P < 0.001).
In the evaluation of Ki-67, the positive staining pattern
was nuclear positive staining in tumor cells. There was
35.6% staining in the seminomas while there was 50.1%
staining in the NSGCTs. No statistical connection was
established between maspin and Ki-67 in the seminoma
cases (P > 0.05). The relation between maspin and Ki-67
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Figure 1. Cytoplasmic brown staining positivity in embryonal carcinoma (A) and seminoma (B) areas and nuclear brown
staining positivity in embryonal carcinoma (C) and seminoma (D) areas for p53.

was statistically insignificant in the NSGCTs (P > 0.05).
In CD31 evaluation, the mean vein count was
calculated in five large magnification areas (5-HPF,
400× magnification). The mean CD31 of the seminoma
cases was 12.2, whereas the mean CD31 of the
nonseminomatous cases was 8.8. No statistical difference
was found between maspin and CD31 in either seminoma
or nonseminomatous tumors (P > 0.05).
4. Discussion
Maspin, which was first discovered in breast tissue and
breast cancer cell lines with the hybridization procedure,
is decreased in invasive and metastatic breast and prostate
cancers (1,2). The tumor suppressor function of maspin
was shown in in vitro studies. Unlike cell adhesion and
other serpins, maspin leads to an increase in apoptosis and
a decrease in cell motility, angiogenesis, and pericellular
proteolysis (1,4). In some experimental studies, maspin
prevented the development and/or progression of
malignant tumors with the p53-dependent pathway,
plasminogen activation inhibition, and angiogenesis

inhibition (11). Studies also suggested that maspin takes
effect through angiogenesis and is associated with VEGF
(12). High maspin expression was shown in normal
human breast and prostate epithelium cells. However,
expression decreased in the cancer cells of these organs
and disappeared in metastases (3–5). Other studies
suggested that increased maspin expression was a good
prognostic factor in oral squamous cell carcinomas (4).
In contrast, increased maspin expression was detected in
pancreas-origin cancers, whereas no maspin expression
was observed in normal pancreas cells (11).
Various reports have suggested that nuclear
and cytoplasmic maspin expression has different
clinicopathologic importance in different types of tumors.
That nuclear positivity was a good prognostic indication
was emphasized in some studies, while in others maspin
positivity was associated with shorter-term survival.
Sood et al. reported that cytoplasmic localization was
related to a poor prognosis, whereas nuclear localization
was associated with benign cases in ovarian cancers (3).
In a study conducted on adenocarcinomas, improved
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morphologic indications were found in patients who
showed nuclear maspin positivity (13). Nakagawa et al.
did not determine a difference between maspin-positive
and -negative groups in terms of prognosis (11). However,
the researchers suggested that cytoplasmic-stained maspin
was a good prognostic factor in renal tumors (7). Maspin
positivity was present in only 1 out of 14 seminoma cases
and 6 out of 18 NSGCT cases in our study. All maspinpositive cases were cytoplasmically stained, and no
nuclear staining was observed in any tumors. Due to the
small number of positively stained tumor cells, it is hard
to say whether cytoplasmic staining is an indication of
a good or bad prognosis. Perhaps different subforms
(active or inactive) of maspin, which was detected
immunohistochemically in the cytoplasm, could exist
at the molecular level, and these forms might reveal the
behavior of maspin in tumors.
Maspin positivity in NSGCTs was significantly higher
than in the seminoma group in our study. Prognosis
for NSGCTs was worse than that for seminomas. No
connection was observed between maspin and tumor
stage, tumor size, or AFP level. Thus, maspin is not a
predictor of a bad prognosis in testicular tumors, but the
fact that it exists more in NSGCTs is an important subject
that should be investigated in wider chain studies.
Along with tumor angiogenesis, VEGF functions as
an autocrine and paracrine growth factor that induces
the proliferation of tumor cells. A connection between
VEGF levels and metastases and/or bad prognosis was
found in many tumors within the body (12–14). Studies
in the literature regarding VEGF and testicular tumors are
lacking. VEGF expression was shown to be significantly
higher in testicular tumors in a study carried out by Fukuda
et al. and in multivariate analyses it was reported that
VEGF displayed significant correlation with metastases
development, especially in seminomas (15). The high
percentage of VEGF staining in our study agreed with the
findings in the literature. Although studies have indicated
a significant relation between maspin and angiogenesis,
this relation was not observed in our study. Likewise, no
relation was discovered between maspin and VEGF in a
previous study conducted on renal tumors (7). Maspin, as
is the case with renal tumors, may have had an effect at the
cellular level with a nonangiogenesis mechanism different
from other tumor groups. Ki-67 is a proliferation kinetics
index used to determine the correct histopathologic
diagnosis, prognosis, and treatment approaches in many
malignant tumors (16).
The Ki-67 index in germ cell tumors in testes is used
to determine a patient’s risk group. Düe et al. investigated
the Ki-67 antibody and the growth pattern of tumors
and proliferative activity immunohistochemically in 20
seminoma cases and found that the growth was between
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50% and 80%. In this study, in which most of the patients’
pathologic stages were advanced, there was a relation
between the tumor pathology and the proliferation rate.
Since the proliferative activity of seminomas determined
their sensitivity to chemotherapy and radiation, it is
advised to look for Ki-67 in these tumors (17). The Ki-67
index of the patients with seminomas was 35.6 and that of
NSGCTs was 50.1 in our study. Statistical analysis showed
no connection between maspin and Ki-67 (P > 0.05).
The p53 tumor suppressor gene located on the
short limb of the 17th chromosome (17pl31) has many
mutations (18). p53 overexpression and mutations
can be seen in many cancers with little differential and
associated poor prognosis. Bostwich et al. reported
that p53 immunoreactivity in urothelial carcinomas
was associated with high tumor stage, degree, vascular
invasion, recurrence, and progression (19). Since p53
expression usually coexists with resistance to radiotherapy
and chemotherapy and the sensitivity of testis GCTs
to radiotherapy and chemotherapy, whether p53
protein expression in GCTs is dependent on a mutation
occurring in the p53 gene has been investigated in many
studies (20,21). Although studies have reported that p53
mutations occur in testicular GCTs, other studies have
reported that the protein expressed in these tumors
is a wild-type p53 protein (19–21). p53 expression in
normal cells suggests a good prognosis. However, p53
overexpression and mutation in tumor cells are associated
with a poor prognosis (18). p53 staining of seminomas
and NSGCTs was evaluated separately in this study. Strong
p53 expression was detected in NSGCTs compared with
seminomas. This result is important in terms of indicating
that mutant p53 was expressed much more than in
NSGCTs with a more aggressive course. In addition, a
statistically positive relation between maspin and p53 in
NSGCTs was demonstrated. Maspin may have displayed
an effect through the p53 pathway in NSGCTs.
CD31 is a molecule in an immunoglobulin superfamily
weighing 130 kDa and generally one of the most widely
used markers for measuring vein density, which is the
arithmetic measurement of tumor angiogenesis (7). In
a study carried out by Yilmazer et al., CD31 and CD34
markers were used for measuring microvein density
(MVD) in renal cell carcinomas (RCCs). Although a
significant relation was detected between CD34 staining
and tumor progression, no correlation between CD31
level and tumor type, stage, nuclear degree, or survival was
observed (22). However, Turunc et al. showed that MVD
measured with the CD31 marker was in counter-relation
to the progression of RCCs and reported that it was a
good prognostic factor (7). The vein count in five large
magnification areas for CD31 was calculated in our study,
and no statistically significant relation was found between
maspin and CD31 in either seminomas or NSGCTs.
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In conclusion, that maspin was expressed in testicular
tumors was first shown in this study. Maspin was
expressed more in NSGCTs compared with seminomas,
but no relation was observed between maspin and tumor
stage and size. Thus, it remains unclear whether maspin is
a poor prognostic factor in testicular tumors. Moreover,
no connection was observed between maspin and VEGF,
Ki-67, or CD31. Therefore, maspin might have affected
testicular tumors through a different method or receptor
at the cellular level apart from angiogenesis or similar

pathways. Thus, the fact that a significant relation was
observed between maspin and p53 makes us think that
maspin could have an effect via the p53 pathway. To
discover the mechanism of action of maspin in testicular
tumors, wider chain studies are needed.
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